Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 23;15(1):130.
doi: 10.1186/s12955-017-0704-y.

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Nancy Devlin  1 , Michael Herdman  2 , Marco Pavesi  3 , De Phung  4 , Shevani Naidoo  5 , Tomasz M Beer  6 , Bertrand Tombal  7 , Yohann Loriot  8 , Cristina Ivanescu  9 , Teresa Parli  10 , Mark Balk  10 , Stefan Holmstrom  11
Affiliations
Clinical Trial

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Nancy Devlin et al. Health Qual Life Outcomes. .

Abstract

Background: The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument.

Methods: Patients received oral enzalutamide 160 mg/day (n = 872) or placebo (n = 845). EQ-5D index and EQ-5D visual analogue scale (EQ-5D VAS) scores were evaluated at baseline, week 13, and every 12 weeks until week 61 due to sample size reduction thereafter. Changes on individual dimensions were assessed, and Paretian Classification of Health Change (PCHC) and time-to-event analyses were conducted.

Results: With enzalutamide, EQ-5D index and EQ-5D VAS scores declined more slowly versus placebo and time to diverge from full health was prolonged. Average decline in EQ-5D index (-0.042 vs. -0.070; P < .0001) and EQ-5D VAS (-1.3 vs. -4.4; P < .0001) was significantly smaller with enzalutamide. There were significant (P < .05) between-group differences favoring enzalutamide in Pain/Discomfort to week 37, Anxiety/Depression at week 13, and Usual Activities at week 25, but no significant differences for Mobility and Self-care. The PCHC analysis showed more enzalutamide patients reporting improvement than placebo patients at weeks 13, 25, and 49 (all P < .05) and week 37 (P = .0512). Enzalutamide was superior (P ≤ .0003) to placebo for time to diverge from full health and time to first deterioration on Pain/Discomfort and Anxiety/Depression dimensions.

Conclusions: This in-depth post hoc analysis showed that enzalutamide delayed HRQoL deterioration and had beneficial effects on several HRQoL domains, including Pain/Discomfort and the proportion of patients in full health, compared with placebo, and may help to support future analyses of this type.

Trial registration: NCT01212991.

Keywords: Enzalutamide; Eq-5D; Metastatic castration-resistant prostate cancer; Quality of life.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Number and proportion of patients in full health (EQ-5D state 11111) at each study visit, by study arm
See this image and copyright information in PMC

References

    1. Sandblom G, Carlsson P, Sennfält K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer. 2004;90:1163–1168. doi: 10.1038/sj.bjc.6601654. - DOI - PMC - PubMed
    1. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16:571–575. doi: 10.1007/s11136-006-9156-2. - DOI - PubMed
    1. Payne H, Pearcy R. Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective. J Mens Health. 2012;9:9–16. doi: 10.1016/j.jomh.2011.11.002. - DOI
    1. Merseburger AS, Bellmunt J, Jenkins C, et al. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18:558–567. doi: 10.1634/theoncologist.2012-0478. - DOI - PMC - PubMed
    1. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6:167–179. doi: 10.1177/1758834014529176. - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources